[Transurethral bipolar plasmakinetic prostatectomy for benign prostatic hyperplasia in high-risk and senior patients in China: a systematic review and meta-analysis]
- PMID: 30884635
- DOI: 10.3760/cma.j.issn.0376-2491.2019.10.015
[Transurethral bipolar plasmakinetic prostatectomy for benign prostatic hyperplasia in high-risk and senior patients in China: a systematic review and meta-analysis]
Abstract
Objective: To evaluate the effectiveness and safety of transurethral bipolar plasmakinetic prostatectomy in the treatment of benign prostatic hyperplasia in high-risk and senior patients in China. Methods: The PubMed, Cochrane Library, CBM, CNKI and WanFang databases were searched with computer for collecting relevant interventional case series from establishment dates to September 14, 2018. After quality evaluation and data extraction independently conducted by two authors, the Meta-analysis was performed using the Comprehensive Meta-analysis V2 software. Results: Eighteen studies involving 1 899 patients are included. Maximum flow rate increased to 12.28 ml/s (95%CI: 8.42-16.14), 12.88 ml/s (95%CI: 9.85-15.92) ,14.32 ml/s (95%CI: 10.47-18.18), 14.93 ml/s (95%CI: 10.19-19.67) and 20.00 ml/s (95%CI: 19.08-20.92) in 1, 3, 6, 12 and 24 months after surgery, respectively. International prostate symptom score decreased to -18.60 (95%CI: -23.20--14.00), -17.62 (95%CI: -20.21--15.03), -19.14 (95%CI: -20.70--17.59), -19.06 (95%CI: -21.53--16.60) and -22.90 (95%CI: -24.26--21.54), respectively. Quality of life decreased to -2.38 (95%CI: -4.26--0.50), -3.39 (95%CI: -4.57--2.21),-3.75 (95%CI: -4.14--3.36), -3.36(95%CI: -4.56--2.16), and -4.58(95%CI: -4.75--4.41). Post void residual decreased to -231.16 ml (95%CI: -288.30--174.01), -76.10 ml (95%CI: -116.71--35.50), -159.90 ml(95%CI: -207.21--112.59) and -87.70 ml (95%CI: -91.91--83.48). The event rate of postoperative adverse reactions all were not high. Conclusion: Transurethral bipolar plasmakinetic prostatectomy has better clinical efficacy and no obvious side effects in the treatment of benign prostatic hyperplasia in high-risk and senior patients in China.
目的： 评价经尿道等离子双极电切术治疗中国高危高龄良性前列腺增生症患者的有效性和安全性。 方法： 计算机检索PubMed、Cochrane Library、CNKI、CBM和万方数据库，搜集经尿道等离子双极电切术治疗中国高危高龄良性前列腺增生症的病例系列研究，检索时间为建库至2018年9月14日。由两名评价者独立提取数据与质量评价，采用Comprehensive Meta-Analysis V2软件进行荟萃分析。 结果： 最终纳入18项研究，共1 899例患者。术后第1、3、6、12和24个月的Q(max)改变量分别为12.28 ml/s（95%CI：8.42~16.14）、12.88 ml/s（95%CI：9.85~15.92）、14.32 ml/s（95%CI：10.47~18.18）、14.93 ml/s（95%CI：10.19~19.67）和20.00 ml/s（95%CI：19.08~20.92）；IPSS评分改变量分别为-18.60（95%CI：-23.20~-14.00）、-17.62（95%CI：-20.21~-15.03）、-19.14（95%CI：-20.70~-17.59）、-19.06（95%CI：-21.53~-16.60）和-22.90（95%CI：-24.26~-21.54）；QoL评分改变量分别为-2.38（95%CI：-4.26~-0.50）、-3.39（95%CI：-4.57~-2.21）、-3.75（95%CI：-4.14~-3.36）、-3.36（95%CI：-4.56~-2.16）和-4.58（95%CI：-4.75~-4.41）；PVR改变量分别为-231.16 ml（95%CI：-288.30~-174.01）、-76.10 ml（95%CI：-116.71~-35.50）、-159.90 ml（95%CI：-207.21~-112.59）和-87.70 ml（95%CI：-91.91~-83.48），术后不良反应发生率均不高。 结论： 经尿道等离子双极电切术治疗高危高龄良性前列腺增生症患者有较好的临床疗效和安全性。.
Keywords: Benign prostatic hyperplasia; High-risk and senior patients; Meta-analysis; Systematic review; Transurethral bipolar plasmakinetic prostatectomy.
Similar articles
-
[Transurethral prostatectomy with the bipolar plasmakinetic technique for benign prostate hyperplasia: a report of 712 cases].Zhonghua Nan Ke Xue. 2009 May;15(5):449-51. Zhonghua Nan Ke Xue. 2009. PMID: 19514560 Chinese.
-
Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis.World J Urol. 2018 Sep;36(9):1355-1364. doi: 10.1007/s00345-018-2287-6. Epub 2018 Apr 12. World J Urol. 2018. PMID: 29651642
-
A comparative study of thulium laser resection of the prostate and bipolar transurethral plasmakinetic prostatectomy for treating benign prostatic hyperplasia.BJU Int. 2013 Apr;111(4):633-7. doi: 10.1111/j.1464-410X.2012.11610.x. Epub 2012 Oct 29. BJU Int. 2013. PMID: 23107074 Clinical Trial.
-
Safety and Efficacy of Thulium Laser Prostatectomy Versus Transurethral Resection of Prostate for Treatment of Benign Prostate Hyperplasia: A Meta-Analysis.Low Urin Tract Symptoms. 2016 Sep;8(3):165-70. doi: 10.1111/luts.12092. Epub 2015 Feb 20. Low Urin Tract Symptoms. 2016. PMID: 27619781 Review.
-
Comparison of transurethral plasmakinetic and transvesical prostatectomy in treatment of 100-149 mL benign prostatic hyperplasia.Asian J Surg. 2014 Apr;37(2):58-64. doi: 10.1016/j.asjsur.2013.04.006. Epub 2013 May 28. Asian J Surg. 2014. PMID: 23726830
Cited by
-
Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition).Mil Med Res. 2022 Apr 1;9(1):14. doi: 10.1186/s40779-022-00371-6. Mil Med Res. 2022. PMID: 35361280 Free PMC article.
-
Comparison of bipolar plasmakinetic resection of prostate versus photoselective vaporization of prostate by a three year retrospective observational study.Sci Rep. 2021 May 12;11(1):10142. doi: 10.1038/s41598-021-89623-4. Sci Rep. 2021. PMID: 33980942 Free PMC article.
-
Therapeutic Effect Analysis of Plasma Bipolar Intelligent Electrotonic for Cystostomy in the Treatment of Senile Prostatic Hyperplasia.J Healthc Eng. 2021 Oct 15;2021:9332848. doi: 10.1155/2021/9332848. eCollection 2021. J Healthc Eng. 2021. Retraction in: J Healthc Eng. 2023 Jul 12;2023:9804341. doi: 10.1155/2023/9804341. PMID: 34691381 Free PMC article. Retracted.
-
Efficacy and Safety of Prostatic Artery Embolization in the Treatment of High Risk Benign Prostatic Hyperplasia and its Influence on Postoperative Life Quality of Patients.Front Surg. 2022 May 17;9:905394. doi: 10.3389/fsurg.2022.905394. eCollection 2022. Front Surg. 2022. PMID: 35656089 Free PMC article.
